T2005010
Triflusal impurity B
European Pharmacopoeia (EP) Reference Standard
Synonim(y):
2-Hydroxy-4-(trifluoromethyl)benzoic acid, 4-(Trifluoromethyl)salicylic acid
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Polecane produkty
klasa czystości
pharmaceutical primary standard
rodzina API
triflusal
producent / nazwa handlowa
EDQM
Zastosowanie
pharmaceutical (small molecule)
format
neat
temp. przechowywania
2-8°C
InChI
1S/C8H5F3O3/c9-8(10,11)4-1-2-5(7(13)14)6(12)3-4/h1-3,12H,(H,13,14)
Klucz InChI
XMLFPUBZFSJWCN-UHFFFAOYSA-N
Opis ogólny
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Zastosowanie
Triflusal impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Opakowanie
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Inne uwagi
Sales restrictions may apply.
This page may contain text that has been machine translated.
Wybierz jedną z najnowszych wersji:
Certyfikaty analizy (CoA)
Przepraszamy, ale COA dla tego produktu nie jest aktualnie dostępny online.
Proszę o kontakt, jeśli potrzebna jest pomoc Obsługa Klienta
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
The Journal of urology, 166(5), 1962-1968 (2001-10-05)
We examined the effects of intravenous administration of the 2 nuclear factor-kappaB inhibitors aspirin and 2-hydroxy-4-trifluoromethylbenzoic acid (HTB) on bladder filling and voiding in anesthetized and conscious rats. Disappearance of isovolumic bladder contractions after intravenous administration of different doses of
European journal of clinical pharmacology, 42(2), 175-179 (1992-01-01)
2-hydroxy-4-trifluoromethylbenzoic acid (HTB) is the main active metabolite of the platelet antiaggregant drug triflusal. Its binding to plasma proteins of rats and healthy volunteers in vitro and in vivo has been studied. Rats were given a single oral dose of
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 798(2), 257-264 (2003-12-04)
A rapid, selective and sensitive high-performance liquid chromatography (HPLC) method was developed and validated for the simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid (HTB), in rat and human plasma. HPLC analysis was carried out using
European journal of clinical pharmacology, 61(2), 103-111 (2005-02-16)
Triflusal has been shown to exert neuroprotective effects by downregulating molecules considered responsible for the development of Alzheimer's disease (AD). The aim of this study was to develop a population pharmacokinetic model to characterize plasma and cerebrospinal fluid (CSF) pharmacokinetics
International journal of clinical pharmacology, therapy, and toxicology, 28(8), 344-349 (1990-08-01)
Triflusal pharmacokinetics were evaluated in 8 healthy subjects after a single 300 mg dose and after repeated doses of 300 mg every 8 h and 600 mg every 24 h during 13 days, with the aim of establishing a relationship
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej